Related Experiment Videos
[Pregnancy and cardiac drugs]
1Service de Cardiologie, Centre hospitalier de Valence.
Revue Francaise De Gynecologie Et D'Obstetrique
|May 1, 1993
Summary
Cardiology medications can often be safely used during pregnancy, but some require caution or avoidance due to potential fetal risks. Careful patient monitoring is crucial for managing maternal and fetal health.
Area of Science:
- Cardiology
- Pharmacology
- Obstetrics
Context:
- Pregnancy necessitates careful consideration of drug effects on fetal development, especially during the first trimester.
- Cardiovascular drug use during pregnancy requires a thorough understanding of both maternal and fetal risks.
Purpose:
- To review the safety and risks of common cardiology medications during pregnancy.
- To provide guidance on drug selection and management for pregnant patients with cardiovascular conditions.
Summary:
- Many cardiovascular drugs, including digitalis, furosemide, certain beta-blockers, verapamil, nifedipine, quinidine, disopyramide, lignocaine, flecainide, amiodarone, heparins, central antihypertensives, dipyridamole, and aspirin, are generally considered safe for use in pregnancy.
- Some medications, such as bumentanide, moxonidine, newer beta-blockers, cibenzoline, and ticlopidine, should be avoided due to insufficient safety data. Others, like spironolactone, bipyridines, diltiazem, and angiotensin-converting enzyme inhibitors, pose risks to the fetus or newborn and should be used with extreme caution or avoided.
- For drugs like propafenone and oral anticoagulants, a risk-benefit analysis comparing maternal disease risks with fetal drug risks is essential.
Impact:
- Informed prescribing practices can minimize adverse maternal and fetal outcomes.
- This review aids healthcare providers in making safer medication choices for pregnant patients with heart conditions.
- Proper management and monitoring can prevent complications and potential medicolegal issues for prescribers.